Why the study?
Does losartan reduce proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease?
Population
32 non-diabetic patients with chronic kidney disease with non-nephrotic-range proteinuria and normal renal…
Comparison
Losartan 50 mg/day, titrated up to 100 mg/day… vs Control group
Design
RCT, randomised to a losartan or a control group
Follow-up
24 months
Key result
Losartan significantly reduced urinary protein excretion by 43% (p<0.0001) and preserved renal function in non-diabetic patients with chronic kidney disease.
Authors
Loading...
Supports losartan for proteinuria in non-diabetic CKD; extends ARB renoprotection evidence beyond diabetes.
RCT (n=32)
Does losartan reduce proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease?
Effect estimate: 43% reduction
p-value: p=<0.0001
Losartan significantly reduces proteinuria and urinary angiotensinogen excretion while preserving renal function in non-diabetic patients with chronic kidney disease.
Lee et al. (2011) conducted an RCT in Chronic kidney disease with non-nephrotic-range proteinuria (n=32). Losartan vs. Control was evaluated on Percentage change in proteinuria (43% reduction, p=<0.0001). Losartan significantly reduced urinary protein excretion by 43% (p<0.0001) and preserved renal function in non-diabetic patients with chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: